Alzheimer's Disease
  • Podcast
  • Jul 3 2019

In this episode of "Behind the Blue," Sanders-Brown director Linda Van Eldik talks about the center's involvement in some of the most important discoveries in the history of Alzheimer's research and what they are doing now to advance the science.

  • Article
  • May 1 2019

In the past, using "Alzheimer’s disease" & "dementia" interchangeably was a generally accepted practice. Now there's rising appreciation that a variety of diseases & disease processes contribute to dementia.

  • Video
  • Apr 3 2019

Linda Van Eldik, director of the UK Sanders-Brown Center on Aging, received $5.5 million from NIH and the Alzheimer's Drug Discovery Foundation. She developed a drug that is ready for its first round of testing in humans.

  • Article
  • Nov 7 2018

Research from the Sanders-Brown Center on Aging presented at the Society for Neuroscience annual meeting has identified two potential ways to predict vascular cognitive impairment and dementia (VCID) – the second leading cause of dementia behind Alzheimer's disease.

  • Article
  • Oct 4 2018

The 8th Annual Sanders-Brown Center on Aging's Markesbery Symposium will take place Oct. 26-27.

  • Article
  • Sep 20 2018

Results from a survey of more than 1,000 U.S. adults showed that while almost 80 percent of respondents were willing to volunteer for medical research, two-thirds didn't know how to get involved.

  • Article
  • Apr 25 2018

The 10th annual Mind Matters Health Fair will feature the latest information on healthy aging.

  • Video
  • Jan 4 2018

Scientists from four different institutions are working together to identify a biomarker for Alzheimer's Disease using mice that travel an 850-mile circuit to test the efficacy of special technology called Quest MRI.

  • Article
  • Dec 20 2017

Science and policy may seem like two unrelated fields, but for Alex Helman, a doctoral candidate in the UK College of Medicine, the two are linked.

  • Video
  • Oct 6 2017

The National Institutes of Health has awarded a five year, $2.88 million grant to a researcher at the Sanders-Brown Center on Aging to study a drug's potential to prevent Alzheimer's disease.